The firm invests in clinical-stage biotech and pharma companies, and provides proprietary technologies and services to equip companies in which the fund invests, giving investors and strategic licensing partners the comfort that the clinical trials have a higher likelihood of success. Prevail Partners seeks to open access to emerging medical technologies for potential partners seeking tomorrow's therapies and treatments.